Morgan Stanley Keeps Their Buy Rating on SAGE Therapeutics (SAGE)

By Ryan Adsit

Morgan Stanley analyst Matthew Harrison maintained a Buy rating on SAGE Therapeutics (SAGEResearch Report) on November 21 and set a price target of $217.00. The company’s shares closed last Monday at $149.00.

According to TipRanks.com, Harrison is a 5-star analyst with an average return of 9.3% and a 59.0% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Vertex Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for SAGE Therapeutics with a $200.38 average price target, which is a 31.7% upside from current levels. In a report issued on November 12, Cowen & Co. also maintained a Buy rating on the stock with a $207.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $193.56 and a one-year low of $79.88. Currently, SAGE Therapeutics has an average volume of 376.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.